Ambu reported that earlier engagement discussions helped shape its sustainability focus. The company has reduced Scope 1 (direct) and 2 (indirect) CO2 emissions by 14 percent per tonne of finished goods and achieved half of its 2030 Science-Based Targets initiative (SBTi) targets. This has been driven by early adoption of bioplastics across its endoscope portfolio and expansion of its Recircle take-back and recycling programme in Europe and the US. Importantly, Ambu highlighted that its improved sustainability credentials have increased competitiveness, contributing to more bids being won as healthcare procurement increasingly favours suppliers with higher sustainability standards.
Ambu’s sharper focus in emerging markets reduces execution risk and improves capital efficiency, while its sustainability progress has delivered measurable emissions reductions and enhanced commercial outcomes through improved tender success.
Looking ahead, our future engagements will focus on supporting Ambu's ability to realise growth in emerging markets and encourage further adoption of sustainability initiatives that we believe will continue to strengthen the company's growth opportunities.